JNJ•benzinga•
Johnson & Johnson Announces Bleximenib, Investigational Selective Menin Inhibitor, Shows Potential As Combination Therapy For Treatment Of Relapsed Or Refractory AML And Newly Diagnosed, Intensive Chemo-Ineligible AML
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on June 12, 2025 by benzinga